Frequency of CYP2C9 and VKORC1 Gene Polymorphisms and Their Influence on Warfarin Dose in Egyptian Pediatric Patients

Overview

Journal Paediatr Drugs

Specialties Pediatrics
Pharmacology

Date 2014 May 7

PMID 24797541

Citations 4

Authors

Mennat-Allah Kamal El-Din

Marwa Salah Farhan

Randa Ibrahim El Shiha

Rania Mohammed Helmy El-Kaffas

Somaia Mohammed Mousa

Affiliations

Soon will be listed here.

Abstract

Introduction: Warfarin is a widely used anticoagulant that shows a high inter-individual variability in the dose needed to achieve target anticoagulation. In adults, common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K epoxide reductase complex (VKORC1) enzymes, in addition to non-genetic factors, explain this dose variability. In children, data about warfarin pharmacogenetics are limited and inconsistent.

Methods: CYP2C9 (*2 and *3) alleles and the VKORC1 (C1173T and G-1639A) polymorphisms were studied by multiplex real time polymerase chain reaction in 41 pediatric patients who received stable warfarin maintenance dose.

Results: The allele frequency of the studied genes was CYP2C9*2 (0.085), CYP2C9*3 (0.12), VKORC1 1173T (0.52), and VKORC1 -1639A (0.54). In univariate analysis, patients' age, weight, and height were significantly (p < 0.0001) associated with warfarin maintenance dose. However, CYP2C9 and VKORC1 gene polymorphisms did not affect warfarin dose. In multivariate analysis, age was found to be the only significant determinant of daily warfarin maintenance dose (p = 0.045).

Conclusion: Age was the most significant determinant of warfarin dosage in this preliminary study including Egyptian pediatric patients. Further studies involving larger numbers of children are warranted to determine the true impact of genetic factors on warfarin doses in pediatric patients.

Citing Articles

polymorphism is associated with an increased risk of familial cancer: evidence from a meta-analysis.

Jiang Y, Zhao C, Cheng L, Xu B, Lv H Hered Cancer Clin Pract. 2017; 15:8.

PMID: 28630657 PMC: 5470195. DOI: 10.1186/s13053-017-0068-7.

The allele frequency of and in the Southern Khorasan population.

Emadian Razavi F, Zarban A, Hajipoor F, Naseri M Res Pharm Sci. 2017; 12(3):211-221.

PMID: 28626479 PMC: 5465830. DOI: 10.4103/1735-5362.207202.

Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.

Takeuchi M, Kobayashi T, Brandao L, Ito S Syst Rev. 2016; 5(1):105.

PMID: 27334984 PMC: 4917995. DOI: 10.1186/s13643-016-0280-y.

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.

Taskin B, Kula S, Ergun M, Altun D, Olgunturk R, Tunaoglu F Anatol J Cardiol. 2016; 16(10):791-796.

PMID: 27182616 PMC: 5324942. DOI: 10.14744/AnatolJCardiol.2015.6150.

References

Shaw K, Amstutz U, Hildebrand C, Rassekh S, Hosking M, Neville K . VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer. 2014; 61(6):1055-62. DOI: 10.1002/pbc.24932. View

Mazzaccara C, Conti V, Liguori R, Simeon V, Toriello M, Severini A . Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. PLoS One. 2013; 8(8):e71505. PMC: 3753327. DOI: 10.1371/journal.pone.0071505. View

El Din M, Amin D, Ragab S, Ashour E, Mohamed M, Mohamed A . Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen. Int J Lab Hematol. 2012; 34(5):517-24. DOI: 10.1111/j.1751-553X.2012.01426.x. View

Shahin M, Khalifa S, Gong Y, Hammad L, Sallam M, El Shafey M . Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics. 2011; 21(3):130-5. PMC: 3038469. DOI: 10.1097/FPC.0b013e3283436b86. View

Moreau C, Bajolle F, Siguret V, Lasne D, Golmard J, Elie C . Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2011; 119(3):861-7. PMC: 3384479. DOI: 10.1182/blood-2011-07-365502. View

Burian M, Grosch S, Tegeder I, Geisslinger G . Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol. 2002; 54(5):518-21. PMC: 1874480. DOI: 10.1046/j.1365-2125.2002.01693.x. View

Kato Y, Ichida F, Saito K, Watanabe K, Hirono K, Miyawaki T . Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab Pharmacokinet. 2011; 26(3):295-9. DOI: 10.2133/dmpk.DMPK-10-NT-082. View

Hamdy S, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Mizugaki M . Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol. 2002; 53(6):596-603. PMC: 1874334. DOI: 10.1046/j.1365-2125.2002.01604.x. View

Manolopoulos V, Ragia G, Tavridou A . Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics. 2010; 11(4):493-6. DOI: 10.2217/pgs.10.31. View

10.

Biss T, Avery P, Brandao L, Chalmers E, Williams M, Grainger J . VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood. 2011; 119(3):868-73. DOI: 10.1182/blood-2011-08-372722. View

11.

Murry D, Crom W, Reddick W, Bhargava R, Evans W . Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos. 1995; 23(10):1110-6. View

12.

Suarez-Kurtz G . Population diversity and the performance of warfarin dosing algorithms. Br J Clin Pharmacol. 2011; 72(3):451-3. PMC: 3175514. DOI: 10.1111/j.1365-2125.2011.04018.x. View

13.

Schelleman H, Limdi N, Kimmel S . Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics. 2008; 9(9):1331-46. DOI: 10.2217/14622416.9.9.1331. View

14.

Ruud E, Holmstrom H, Bergan S, Wesenberg F . Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. Pediatr Blood Cancer. 2007; 50(3):710-3. DOI: 10.1002/pbc.21133. View

15.

Nowak-Gottl U, Dietrich K, Schaffranek D, Eldin N, Yasui Y, Geisen C . In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 2010; 116(26):6101-5. DOI: 10.1182/blood-2010-05-283861. View

16.

Takahashi H, Ishikawa S, Nomoto S, Nishigaki Y, Ando F, Kashima T . Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther. 2000; 68(5):541-55. DOI: 10.1067/mcp.2000.110977. View

17.

Nguyen N, Anley P, Yu M, Zhang G, Thompson A, Jennings L . Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatr Cardiol. 2012; 34(4):984-90. DOI: 10.1007/s00246-012-0592-1. View

18.

Johnson J, Gong L, Whirl-Carrillo M, Gage B, Scott S, Stein C . Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011; 90(4):625-9. PMC: 3187550. DOI: 10.1038/clpt.2011.185. View

19.

Eriksson N, Wadelius M . Prediction of warfarin dose: why, when and how?. Pharmacogenomics. 2012; 13(4):429-40. DOI: 10.2217/pgs.11.184. View